Acute mitochondrial antioxidant intake improves endothelial function, antioxidant enzyme activity, and exercise tolerance in patients with peripheral artery disease

Authors

Song-young Park, University of Nebraska at OmahaFollow
Elizabeth J. Pekas, University of Nebraska at OmahaFollow
Ronald Headid III, University of Nebraska at OmahaFollow
Won-Mok Son, University of Nebraska at OmahaFollow
TeSean Wooden, University of Nebraska at OmahaFollow
Jiwon Song, University of Nebraska at OmahaFollow
Gwenael Layec, Veterans Affairs Medical Center
Santosh K. Yadav, University of Nebraska Medical Center
Paras K. Mishra, University of Nebraska at Omaha
Iraklis Pipinos, University of Nebraska at OmahaFollow

Author ORCID Identifier

Park - https://orcid.org/0000-0001-8576-7531

Yadav https://orcid.org/0000-0001-9728-4561

Document Type

Article

Publication Date

8-4-2020

Publication Title

American Journal of Physiology Heart and Circulatory Physiology

Volume

319

Issue

2

First Page

H456

Last Page

H467

Abstract

Peripheral artery disease (PAD) is a manifestation of atherosclerosis in the leg arteries, which causes claudication. This may be in part due to vascular mitochondrial dysfunction and excessive reactive oxygen species (ROS) production. A mitochondrial-targeted antioxidant (MitoQ) has been shown to improve vascular mitochondrial function that, in turn, led to improved vascular function in older adults and animal models. However, the roles of vascular mitochondria in vascular function including endothelial function and arterial stiffness in patients with PAD are unknown; therefore, with the use of acute MitoQ intake, this study examined the roles of vascular mitochondria in endothelial function, arterial stiffness, exercise tolerance, and skeletal muscle function in patients with PAD. Eleven patients with PAD received either MitoQ or placebo in a randomized crossover design. At each visit, blood samples, brachial and popliteal artery flow-mediated dilation (FMD), peripheral and central pulse-wave velocity (PWV), blood pressure (BP), maximal walking capacity, time to claudication (COT), and oxygen utility capacity were measured pre- and-post-MitoQ and placebo. There were significant group by time interactions (P < 0.05) for brachial and popliteal FMD that both increased by Δ2.6 and Δ3.3%, respectively, and increases superoxide dismutase (Δ0.03 U/mL), maximal walking time (Δ73.8 s), maximal walking distance (Δ49.3 m), and COT (Δ44.2 s). There were no changes in resting heart rate, BP, malondialdehyde, total antioxidant capacity, PWV, or oxygen utility capacity (P > 0.05). MitoQ intake may be an effective strategy for targeting the vascular mitochondrial environment, which may be useful for restoring endothelial function, leg pain, and walking time in patients with PAD.

Comments

This is the accepted manuscript of an article published in the American Journal of Physiology - Heart and Circulatory Physiology on August 4, 2020 and can be accessed at https://doi.org/10.1152/ajpheart.00235.2020

Recommended Citation

Acute mitochondrial antioxidant intake improves endothelial function, antioxidant enzyme activity, and exercise tolerance in patients with peripheral artery disease Song-Young Park, Elizabeth J. Pekas, Ronald J. Headid 3rd, Won-Mok Son, TeSean K. Wooden, Jiwon Song, Gwenael Layec, Santosh K. Yadav, Paras K. Mishra, and Iraklis I. Pipinos American Journal of Physiology-Heart and Circulatory Physiology 2020 319:2, H456-H467